Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 17/307% above fair value
$69.39+3.19 (+4.82%)
Close on Oct 30, 2026Market cap $17.19BP/E 20.8Yield –
Earnings
Exelixis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$658.70M
+10.2% on a year earlier
Non-GAAP Diluted EPS, Q3 FY2026
$0.94
$0.78 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 6 items
Quarterly results
Revenue and earnings per share from each of Exelixis's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Jan 2, 2027 | Jan 11, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Oct 2, 2026 | Oct 29, 2026after the close | $658.70M | +10.2% | $0.85 | $0.94 | Release |
| Q2 FY2026ended Jul 3, 2026 | Aug 5, 2026during market hours | $628.70M | +10.6% | $0.82 | $0.91 | Release |
| Q1 FY2026ended Apr 3, 2026 | May 5, 2026during market hours | $610.80M | +10.0% | $0.79 | $0.87 | Release |
| Q4 FY2025ended Jan 2, 2026 | Jan 12, 2026during market hours | – | – | – | – | Release |
| Q3 FY2025ended Oct 3, 2025 | Nov 4, 2025during market hours | $597.80M | +10.8% | $0.69 | $0.78 | Release |
| Q2 FY2025ended Jul 4, 2025 | Jul 28, 2025during market hours | $568.30M | -10.8% | $0.65 | $0.75 | Release |
| Q1 FY2025ended Apr 4, 2025 | May 13, 2025during market hours | $555.40M | +30.6% | $0.55 | $0.62 | Release |
| Q4 FY2024ended Jan 3, 2025 | Jan 13, 2025during market hours | – | – | – | – | Release |
| Q3 FY2024ended Sep 27, 2024 | Oct 29, 2024during market hours | $539.50M | +14.3% | $0.40 | $0.47 | Release |
| Q2 FY2024ended Jun 28, 2024 | Aug 6, 2024during market hours | $637.20M | +35.6% | $0.77 | $0.84 | Release |
| Q1 FY2024ended Mar 29, 2024 | Apr 30, 2024during market hours | $425.20M | +4.0% | $0.12 | $0.17 | Release |
| Q4 FY2023ended Dec 29, 2023 | Jan 8, 2024before the open | – | – | – | – | Release |
| Q3 FY2023ended Sep 29, 2023 | Nov 1, 2023during market hours | $471.90M | +14.6% | $0.00 | $0.10 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023during market hours | $469.80M | +12.0% | $0.25 | $0.31 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $408.80M | +14.8% | $0.12 | $0.16 | Release |
| Q4 FY2022ended Dec 30, 2022 | Jan 9, 2023during market hours | $415.00M | +38.3% | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022during market hours | $411.70M | +25.4% | $0.23 | $0.31 | Release |
| Q2 FY2022ended Jul 1, 2022 | Aug 9, 2022during market hours | $419.40M | – | $0.22 | $0.28 | Release |
| Q1 FY2022ended Apr 1, 2022 | May 10, 2022during market hours | $356.00M | – | $0.21 | $0.26 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 10, 2022during market hours | $300.00M | – | – | – | Release |
| Q3 FY2021ended Oct 1, 2021 | Nov 2, 2021during market hours | $328.40M | – | $0.12 | $0.20 | Release |
| Q2 FY2021ended Jul 2, 2021 | Aug 5, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Apr 2, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Jan 1, 2021 | Jan 11, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Oct 2, 2020 | Nov 5, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Exelixis's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenues | FY2026 | $2.50B – $2.55B | – | New | Oct 29, 2026 |
| Total revenues | FY2026 | $2.50B – $2.55B | $2.53B – $2.63B | Raised | Aug 5, 2026 |
| Cost of goods sold, % of net product revenues | FY2026 | 4% | – | New | Oct 29, 2026 |
| Cost of goods sold, % of net product revenues | FY2026 | 3.5% – 4.5% | 3.5% – 4.5% | Lowered | Aug 5, 2026 |
| Effective tax rate | FY2026 | 16% – 18% | – | Raised | Oct 29, 2026 |
| Effective tax rate | FY2026 | 21% – 23% | 21% – 23% | Raised | Aug 5, 2026 |
| Net product revenues | FY2026 | $2.30B – $2.35B | – | Raised | Aug 5, 2026 |
| Research and development expenses | FY2026 | $825.00M – $875.00M | – | New | Oct 29, 2026 |
| Research and development expenses | FY2026 | $825.00M – $875.00M | $875.00M – $925.00M | Lowered | Aug 5, 2026 |
| Selling, general and administrative expenses | FY2026 | $575.00M – $625.00M | – | Lowered | Oct 29, 2026 |
| Selling, general and administrative expenses | FY2026 | $575.00M – $625.00M | $575.00M – $625.00M | Lowered | Aug 5, 2026 |
Guidance history
Every forecast Exelixis put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Cost of goods sold, % of net product revenues | FY2026 | 4% | New |
| Oct 29, 2026 | Effective tax rate | FY2026 | 16% – 18% | Raised |
| Oct 29, 2026 | Research and development expenses | FY2026 | $825.00M – $875.00M | New |
| Oct 29, 2026 | Selling, general and administrative expenses | FY2026 | $575.00M – $625.00M | Lowered |
| Oct 29, 2026 | Total revenues | FY2026 | $2.50B – $2.55B | New |
| Oct 29, 2026 | Net product revenues | FY2026 | $2.30B – $2.35B | Lowered |
| Aug 5, 2026 | Cost of goods sold, % of net product revenues | FY2026 | 3.5% – 4.5% | Lowered |
| Aug 5, 2026 | Effective tax rate | FY2026 | 21% – 23% | Raised |
| Aug 5, 2026 | Net product revenues | FY2026 | $2.30B – $2.35B | Raised |
| Aug 5, 2026 | Research and development expenses | FY2026 | $825.00M – $875.00M | Lowered |
| Aug 5, 2026 | Selling, general and administrative expenses | FY2026 | $575.00M – $625.00M | Lowered |
| Aug 5, 2026 | Total revenues | FY2026 | $2.50B – $2.55B | Raised |
| Jan 12, 2026 | Cost of goods sold, % of net product revenues | FY2026 | 3.5% – 4.5% | New |
| Jan 12, 2026 | Effective tax rate | FY2026 | 21% – 23% | Raised |
| Jan 12, 2026 | Research and development expenses | FY2026 | $875.00M – $925.00M | New |
| Jan 12, 2026 | Selling, general and administrative expenses | FY2026 | $575.00M – $625.00M | Lowered |
| Jan 12, 2026 | Total revenues | FY2026 | $2.53B – $2.63B | New |
| Jan 12, 2026 | Net product revenues | FY2026 | $2.33B – $2.43B | Lowered |
| Nov 4, 2025 | Cost of goods sold | FY2025 | 4% | Lowered |
| Nov 4, 2025 | Effective tax rate | FY2025 | 17% – 18% | Raised |
| Nov 4, 2025 | Net product revenues | FY2025 | $2.10B – $2.15B | Raised |
| Nov 4, 2025 | Research and development expenses | FY2025 | $850.00M – $900.00M | Lowered |
| Nov 4, 2025 | Selling, general and administrative expenses | FY2025 | $500.00M – $525.00M | Lowered |
| Nov 4, 2025 | Total revenues | FY2025 | $2.30B – $2.35B | Raised |
| Jul 28, 2025 | Cost of goods sold | FY2025 | 4% – 5% | New |
| Jul 28, 2025 | Effective tax rate | FY2025 | 21% – 23% | Raised |
| Jul 28, 2025 | Research and development expenses | FY2025 | $925.00M – $975.00M | New |
| Jul 28, 2025 | Selling, general and administrative expenses | FY2025 | $475.00M – $525.00M | Lowered |
| Jul 28, 2025 | Total revenues | FY2025 | $2.25B – $2.35B | New |
| Jul 28, 2025 | Net product revenues | FY2025 | $2.05B – $2.15B | Lowered |
| May 13, 2025 | Cost of goods sold | FY2025 | 4% – 5% | New |
| May 13, 2025 | Effective tax rate | FY2025 | 21% – 23% | Raised |
| May 13, 2025 | Research and development expenses | FY2025 | $925.00M – $975.00M | New |
| May 13, 2025 | Selling, general and administrative expenses | FY2025 | $475.00M – $525.00M | Lowered |
| May 13, 2025 | Total revenues | FY2025 | $2.25B – $2.35B | New |
| May 13, 2025 | Net product revenues | FY2025 | $2.05B – $2.15B | Lowered |
| Oct 29, 2024 | Cost of goods sold | FY2024 | 4.5% | Lowered |
| Oct 29, 2024 | Effective tax rate | FY2024 | 21% – 22% | Raised |
| Oct 29, 2024 | Research and development expenses | FY2024 | $925.00M – $950.00M | Raised |
| Oct 29, 2024 | Selling, general and administrative expenses | FY2024 | $475.00M – $500.00M | Lowered |
| Oct 29, 2024 | Total revenues | FY2024 | $2.15B – $2.20B | Raised |
| Oct 29, 2024 | Net product revenues | FY2024 | $1.78B – $1.83B | Lowered |
| Aug 6, 2024 | Cost of goods sold | FY2024 | 4% – 5% | Lowered |
| Aug 6, 2024 | Effective tax rate | FY2024 | 20% – 22% | Raised |
| Aug 6, 2024 | Net product revenues | FY2024 | $1.65B – $1.75B | Raised |
| Aug 6, 2024 | Research and development expenses | FY2024 | $925.00M – $975.00M | Lowered |
| Aug 6, 2024 | Selling, general and administrative expenses | FY2024 | $450.00M – $500.00M | Lowered |
| Aug 6, 2024 | Total revenues | FY2024 | $1.98B – $2.08B | Raised |
| Apr 30, 2024 | Cost of goods sold | FY2024 | 4% – 5% | Lowered |
| Apr 30, 2024 | Effective tax rate | FY2024 | 20% – 22% | Raised |
| Apr 30, 2024 | Research and development expenses | FY2024 | $925.00M – $975.00M | Raised |
| Apr 30, 2024 | Selling, general and administrative expenses | FY2024 | $425.00M – $475.00M | Lowered |
| Apr 30, 2024 | Total revenues | FY2024 | $1.83B – $1.93B | Reaffirmed |
| Apr 30, 2024 | Net product revenues | FY2024 | $1.65B – $1.75B | Lowered |
| Jan 8, 2024 | Cost of goods sold | FY2024 | 4% – 5% | New |
| Jan 8, 2024 | Effective tax rate | FY2024 | 20% – 22% | Raised |
| Jan 8, 2024 | Net product revenues | FY2024 | $1.65B – $1.75B | New |
| Jan 8, 2024 | Research and development expenses | FY2024 | $925.00M – $975.00M | Lowered |
| Jan 8, 2024 | Selling, general and administrative expenses | FY2024 | $425.00M – $475.00M | Lowered |
| Jan 8, 2024 | Total revenues | FY2024 | $1.83B – $1.93B | New |
| Nov 1, 2023 | Cost of goods sold | FY2023 | 4% – 5% | Lowered |
| Nov 1, 2023 | Effective tax rate | FY2023 | 20% – 22% | Raised |
| Nov 1, 2023 | Research and development expenses | FY2023 | $1.05B – $1.08B | Raised |
| Nov 1, 2023 | Selling, general and administrative expenses | FY2023 | $525.00M – $550.00M | Lowered |
| Nov 1, 2023 | Total revenues | FY2023 | $1.83B – $1.85B | Narrowed |
| Nov 1, 2023 | Net product revenues | FY2023 | $1.63B – $1.65B | Lowered |
| Aug 1, 2023 | Cost of goods sold | FY2023 | 4% – 5% | Lowered |
| Aug 1, 2023 | Effective tax rate | FY2023 | 20% – 22% | Raised |
| Aug 1, 2023 | Net product revenues | FY2023 | $1.58B – $1.68B | Raised |
| Aug 1, 2023 | Research and development expenses | FY2023 | $1.00B – $1.05B | Lowered |
| Aug 1, 2023 | Selling, general and administrative expenses | FY2023 | $475.00M – $525.00M | Lowered |
| Aug 1, 2023 | Total revenues | FY2023 | $1.78B – $1.88B | Raised |
| May 9, 2023 | Research and development expenses (1) | FY2023 | $1.00B – $1.05B | Raised |
| May 9, 2023 | Selling, general and administrative expenses (2) | FY2023 | $475.00M – $525.00M | Lowered |
| May 9, 2023 | Effective tax rate | FY2023 | 20% – 22% | Raised |
| May 9, 2023 | Cost of goods sold | FY2023 | 4% – 5% | Lowered |
| May 9, 2023 | Total revenues | FY2023 | $1.78B – $1.88B | Raised |
| May 9, 2023 | Net product revenues | FY2023 | $1.58B – $1.68B | Lowered |
| Jan 9, 2023 | Research and development expenses | FY2023 | $1.00B – $1.05B | New |
| Jan 9, 2023 | Cost of goods sold | FY2023 | 4% – 5% | New |
| Jan 9, 2023 | Effective tax rate | FY2023 | 20% – 22% | Raised |
| Jan 9, 2023 | Selling, general and administrative expenses | FY2023 | $475.00M – $525.00M | Lowered |
| Jan 9, 2023 | Total revenues | FY2023 | $1.78B – $1.88B | New |
| Jan 9, 2023 | Net product revenues | FY2023 | $1.58B – $1.68B | Lowered |
| Nov 1, 2022 | Cost of goods sold | FY2022 | 5% | Lowered |
| Nov 1, 2022 | Effective tax rate | FY2022 | 20% – 22% | Raised |
| Nov 1, 2022 | Net product revenues | FY2022 | $1.38B – $1.40B | Raised |
| Nov 1, 2022 | Research and development expenses | FY2022 | $875.00M – $900.00M | Lowered |
| Nov 1, 2022 | Selling, general and administrative expenses | FY2022 | $450.00M – $475.00M | Lowered |
| Nov 1, 2022 | Total revenues | FY2022 | $1.58B – $1.60B | Narrowed |
| Aug 9, 2022 | Cost of goods sold | FY2022 | 5% – 6% | Lowered |
| Aug 9, 2022 | Effective tax rate | FY2022 | 20% – 22% | Raised |
| Aug 9, 2022 | Net product revenues | FY2022 | $1.33B – $1.43B | Reaffirmed |
| Aug 9, 2022 | Research and development expenses (1) | FY2022 | $725.00M – $775.00M | Lowered |
| Aug 9, 2022 | Selling, general and administrative expenses (2) | FY2022 | $400.00M – $450.00M | Lowered |
| Aug 9, 2022 | Total revenues | FY2022 | $1.53B – $1.63B | Reaffirmed |
| May 10, 2022 | Cost of goods sold | FY2022 | 5% – 6% | Lowered |
| May 10, 2022 | Effective tax rate | FY2022 | 20% – 22% | Raised |
| May 10, 2022 | Net product revenues | FY2022 | $1.33B – $1.43B | Raised |
| May 10, 2022 | Research and development expenses (1) | FY2022 | $725.00M – $775.00M | New |
| May 10, 2022 | Selling, general and administrative expenses (2) | FY2022 | $400.00M – $450.00M | Lowered |
| May 10, 2022 | Total revenues | FY2022 | $1.53B – $1.63B | Raised |
| Jan 10, 2022 | Cost of goods sold | FY2022 | 5% – 6% | New |
| Jan 10, 2022 | Effective tax rate | FY2022 | 20% – 22% | Raised |
| Jan 10, 2022 | Research and development expenses | FY2022 | $725.00M – $775.00M | New |
| Jan 10, 2022 | Selling, general and administrative expenses | FY2022 | $400.00M – $450.00M | Lowered |
| Jan 10, 2022 | Net product revenues | FY2022 | $1.33B – $1.43B | New |
| Nov 2, 2021 | Cost of goods sold | FY2021 | 5% – 6% | New |
| Nov 2, 2021 | Effective tax rate | FY2021 | 20% – 22% | Raised |
| Nov 2, 2021 | Net product revenues | FY2021 | $1.05B – $1.10B | New |
| Nov 2, 2021 | Research and development expenses | FY2021 | $650.00M – $675.00M | Lowered |
| Nov 2, 2021 | Selling, general and administrative expenses | FY2021 | $400.00M – $425.00M | Lowered |
| Nov 2, 2021 | Cash and investments | FY2021 | $1.80B | Raised |
| Nov 2, 2021 | Total revenues | FY2021 | $1.30B – $1.35B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Exelixis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results